The National Institute for Health and Care Excellence (NICE) does not recommend SMBG for people with non-insulin treated T2D unless during pregnancy or in people at risk of hypoglycaemia, due to minimal clinical benefit, increased burden and cost22, 23. This evidence concerns the gene INS and type 2 diabetes mellitus.